BR112023019056A2 - Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte - Google Patents
Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepteInfo
- Publication number
- BR112023019056A2 BR112023019056A2 BR112023019056A BR112023019056A BR112023019056A2 BR 112023019056 A2 BR112023019056 A2 BR 112023019056A2 BR 112023019056 A BR112023019056 A BR 112023019056A BR 112023019056 A BR112023019056 A BR 112023019056A BR 112023019056 A2 BR112023019056 A2 BR 112023019056A2
- Authority
- BR
- Brazil
- Prior art keywords
- aav2
- methods
- amino acid
- acid sequence
- capsid protein
- Prior art date
Links
- 241000702423 Adeno-associated virus - 2 Species 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 3
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 208000022873 Ocular disease Diseases 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 229960002833 aflibercept Drugs 0.000 abstract 1
- 108010081667 aflibercept Proteins 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte. são fornecidos métodos para tratar uma doença ocular em um indivíduo compreendendo a administração de uma dose unitária de partículas de vírus adenoassociado recombinante (raav) a um olho do indivíduo, em que as partículas de raav compreendem: a) um ácido nucleico que codifica um polipeptídeo compreendendo um sequência de aminoácidos com pelo menos cerca de 95% de identidade com a sequência de aminoácidos de seq id nº: 35 e flanqueada por repetições terminais invertidas (itrs) de aav2, e b) uma proteína do capsídeo de aav2 compreendendo uma sequência de aminoácidos lgettrp (seq id nº: 14) inserido entre as posições 587 e 588 da proteína do capsídeo, em que a numeração dos resíduos de aminoácidos corresponde a uma proteína do capsídeo de aav2 vp1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163180646P | 2021-04-27 | 2021-04-27 | |
PCT/US2022/071937 WO2022232790A1 (en) | 2021-04-27 | 2022-04-26 | Methods of treating ocular diseases using aav2 variants encoding aflibercept |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023019056A2 true BR112023019056A2 (pt) | 2024-01-16 |
Family
ID=81984711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023019056A BR112023019056A2 (pt) | 2021-04-27 | 2022-04-26 | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4329721A1 (pt) |
JP (1) | JP2024515459A (pt) |
KR (1) | KR20240005764A (pt) |
CN (1) | CN117222400A (pt) |
BR (1) | BR112023019056A2 (pt) |
CA (1) | CA3215855A1 (pt) |
WO (1) | WO2022232790A1 (pt) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2699270B1 (en) | 2011-04-22 | 2017-06-21 | The Regents of The University of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
AU2017257169B2 (en) * | 2016-04-29 | 2021-07-08 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
KR102218265B1 (ko) * | 2016-06-16 | 2021-02-25 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | Aav2 변이체를 아플리베르셉트와 함께 사용하는 amd의 치료 |
MX2019011040A (es) | 2017-03-17 | 2020-01-20 | Adverum Biotechnologies Inc | Composiciones y metodos para potenciar la expresion genica. |
BR112022003206A2 (pt) * | 2019-09-11 | 2022-08-16 | Adverum Biotechnologies Inc | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte |
JP2022547541A (ja) | 2019-09-11 | 2022-11-14 | アドヴェラム バイオテクノロジーズ, インコーポレイテッド | アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法 |
WO2021050094A1 (en) | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
-
2022
- 2022-04-26 JP JP2023558203A patent/JP2024515459A/ja active Pending
- 2022-04-26 KR KR1020237040171A patent/KR20240005764A/ko unknown
- 2022-04-26 CN CN202280030462.0A patent/CN117222400A/zh active Pending
- 2022-04-26 CA CA3215855A patent/CA3215855A1/en active Pending
- 2022-04-26 BR BR112023019056A patent/BR112023019056A2/pt unknown
- 2022-04-26 WO PCT/US2022/071937 patent/WO2022232790A1/en active Application Filing
- 2022-04-26 EP EP22729004.6A patent/EP4329721A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20240005764A (ko) | 2024-01-12 |
JP2024515459A (ja) | 2024-04-10 |
CA3215855A1 (en) | 2022-11-03 |
CN117222400A (zh) | 2023-12-12 |
WO2022232790A1 (en) | 2022-11-03 |
EP4329721A1 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022004027A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
PH12020550094A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
PH12020550706A1 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
JP2020510428A5 (pt) | ||
MX2023009627A (es) | Capsides variantes de virus adenoasociados y metodos de uso de las mismas. | |
MX2021011963A (es) | Virus adeno-asociados recombinantes y sus usos. | |
MX2021005517A (es) | Terapia genica para lipofuscinosis neuronal ceroidea. | |
WO2001016330A3 (en) | Prevention of affections associated with porcine circovirus-2 | |
MXPA02011545A (es) | Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela. | |
RU2011122201A (ru) | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора | |
DE23193601T1 (de) | Verfahren zur erhöhung der funktion eines aav-vektors | |
CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
PE20191261A1 (es) | Composiciones utiles para el tratamiento de atrofia muscular espinal | |
AR124119A2 (es) | Partículas virales modificadas y usos de estas | |
MX2021013364A (es) | Composiciones utiles para el tratamiento de la enfermedad de pompe. | |
PE20220930A1 (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica | |
BR112022019729A2 (pt) | Repetição terminal invertida (itr), vetor de ácido nucleico, partícula de vírus adenoassociado recombinante, composição farmacêutica e métodos de entrega de um ácido nucleico e de prevenção ou tratamento de uma doença | |
CO2022015313A2 (es) | Variantes de cápsides de aav y usos de los mismos | |
BR112022003206A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
RU2019126509A (ru) | Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе | |
BR112023019056A2 (pt) | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte | |
MX2022007135A (es) | Vectores de virus adenoasociados para el tratamiento del síndrome de hunter. | |
CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
AR119955A1 (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept |